GlassScriptPhysician profile
Venus R Rivera
NPI 1720269681
$5,869.66
in general payments reported to CMS, 2019-2025
30 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $498 · 2021: $1,720 · 2022: $1,120 · 2023: $857 · 2024: $383 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $1,942.17 | 2021-2024 | |
| Axogen | $691.27 | 2019-2021 | |
| Abbvie INC. | $658.08 | 2023-2025 | Alloderm, Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $364.98 | 2019-2022 | |
| Mentor Worldwide LLC | $317.22 | 2019-2021 | |
| Merz North America, INC. | $242.75 | 2019-2025 | |
| Integra Lifesciences Corporation | $214.34 | 2020-2023 | Integra, Instruments-Orthopedic, Codman Isocool Aht |
| Ethicon US, LLC | $179.85 | 2019 | |
| Sientra, INC. | $159.81 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $154.85 | 2021-2022 | |
| Smith+Nephew, INC. | $115.32 | 2019-2021 | |
| Melinta Therapeutics, LLC | $113.63 | 2019-2020 | |
| Tela Bio, INC. | $99.79 | 2019-2020 | |
| Revance Therapeutics, INC. | $93.31 | 2024 | Daxxify |
| Heron Therapeutics, INC. | $54.31 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $52.20 | 2019-2022 | |
| Galderma Laboratories, L.P. | $50.83 | 2025 | Dysport |
| Kci USA, INC. | $50.16 | 2019-2021 | |
| Stryker Corporation | $49.13 | 2019-2023 | Spy-Phi System |
| Olympus America INC. | $37.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $37.10 | 2023 | Dsuvia |
| Ets Wound Care LLC | $30.36 | 2025 | Mirragen Advanced Wound Matrix |
| Acell, INC. | $24.45 | 2020 | |
| Mckesson Medical-Surgical, INC. | $23.47 | 2022 | |
| Reprise Biomedical, INC. | $22.07 | 2020 | |
| Eagle Pharmaceuticals, INC. | $21.08 | 2023 | |
| Medtronic USA, INC. | $20.05 | 2020 | |
| Molnlycke Health Care US, LLC | $18.00 | 2023 | Avance, Mepilex Border Ag |
| Amniox Medical, INC. | $16.87 | 2019 | |
| Kerecis Limited | $14.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venus Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.